CLDX - Celldex Therapeutics, Inc.
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Currency in USD
Valuation measures4
| Market cap (intra-day) | 1.57B |
| Enterprise value | 1.27B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 496.63 |
| Price/book (mrq) | 5.19 |
| Enterprise value/revenue | 403.70 |
| Enterprise value/EBITDA | -11.26 |
Trading information
Stock price history
| Beta (5Y monthly) | 2.10 |
| 52-week change 3 | 40.34% |
| S&P500 52-week change 3 | 3.90% |
| 52-week high 3 | 48.40 |
| 52-week low 3 | 19.85 |
| 50-day moving average 3 | 33.18 |
| 200-day moving average 3 | 36.57 |
Share statistics
| Avg vol (3-month) 3 | 615.46k |
| Avg vol (10-day) 3 | 335.13k |
| Shares outstanding 5 | 47.25M |
| Implied shares outstanding 6 | N/A |
| Float 8 | 44.02M |
| % held by insiders 1 | 0.31% |
| % held by institutions 1 | 105.55% |
| Shares short (14 May 2023) 4 | 5.42M |
| Short ratio (14 May 2023) 4 | 9.21 |
| Short % of float (14 May 2023) 4 | 13.93% |
| Short % of shares outstanding (14 May 2023) 4 | 11.46% |
| Shares short (prior month 13 Apr 2023) 4 | 5.18M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 10 Feb 2019 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:15 |
| Last split date 3 | 10 Feb 2019 |
Financial highlights
Fiscal year
| Fiscal year ends | 30 Dec 2022 |
| Most-recent quarter (mrq) | 30 Mar 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -3,675.37% |
Management effectiveness
| Return on assets (ttm) | -19.33% |
| Return on equity (ttm) | -33.86% |
Income statement
| Revenue (ttm) | 3.15M |
| Revenue per share (ttm) | 0.07 |
| Quarterly revenue growth (yoy) | 455.70% |
| Gross profit (ttm) | -79.9M |
| EBITDA | -112.96M |
| Net income avi to common (ttm) | -118.64M |
| Diluted EPS (ttm) | -2.56 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 278.39M |
| Total cash per share (mrq) | 5.89 |
| Total debt (mrq) | 3.65M |
| Total debt/equity (mrq) | 1.21 |
| Current ratio (mrq) | 19.03 |
| Book value per share (mrq) | 6.41 |
Cash flow statement
| Operating cash flow (ttm) | -107.77M |
| Levered free cash flow (ttm) | -54.6M |
© 2023 Yahoo. All rights reserved.